FluoGuide is presenting at Redeye’s Orphan Drugs on the 27 April 2022
April 20, 2022
Copenhagen, Denmark, 20 April 2022 – FluoGuide A/S (“FluoGuide” or the “Company”) is pleased to announce that Morten Albrechtsen, CEO of FluoGuide will present at Redeye’s Orphan Drugs in the afternoon of the 27th of April. More information is available on https://fluoguide.com/investor/calendar-events/
FluoGuide’s primary focus is to maximize surgical outcomes in oncology. The Company’s lead product, FG001, is designed to improve surgical precision by illuminating cancer cells intraoperatively. The improved precision enabled by FluoGuide’s products has a dual benefit – it reduces both the frequency of local recurrence post-surgery and lessens surgical sequelae. Ultimately, the improved precision will improve a patient’s chance of achieving a complete cure and will lower system-wide healthcare costs. The Company is has demonstrated early evidence of efficacy of F001 as well as it to be well tolerated and safe in the ongoing proof-of-concept clinical study (phase I/II) in patients with high grade glioma undergoing surgery. FluoGuide is listed on Nasdaq First North Sweden under the ticker “FLUO”.
For more information on the Company’s uPAR technology platform and our pipeline please visit our home page www.fluoguide.com